As our previous studies have showed MUC4 stabilization and interaction with HER2 [14, 15], we examined whether canertinib could influence the localization pattern of MUC4 and HER2 in pancreatic cancer cells by immunofluorescence analysis. This evidence concerns the gene MUC4 and familial pancreatic carcinoma.